You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

63 search results for: disease control

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Un<b>control</b>led and/or Severe CRSwNP

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

expert video

Guideline and Patient Management in CSU

4 min

Dermatology

Drs. Maurer and Ensina discuss cutting-edge strategies for managing CSU in this insightful interview.

expert video

Treatment Goals, Current and Emerging Therapies in CSU

6 min

Dermatology

Drs. Maurer and Ensina delve into their thoughts on the latest treatment goals and emerging therapies for CSU in this illuminating interview.

expert video

GOLD 2023 | Clinical Presentation of COPD and Disease Burden

9 min

Pulmonology

Dr. Igor Barjaktarevic discusses the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.

New Perspectives on <b>Disease</b> Modification in Atopic Dermatitis

expert video

New Perspectives on Disease Modification in Atopic Dermatitis

48 min

Dermatology

An exploration into the concept and potential of disease modification through therapeutic interventions in AD.

What proportion of patients can achieve <b>control</b> in CRSwNP?

expert video

What proportion of patients can achieve control in CRSwNP?

5 min

Rhinology

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.

Exploring The Concept of <b>Disease</b> Modification in Atopic Dermatitis

expert video

Exploring The Concept of Disease Modification in Atopic Dermatitis

13 min

Dermatology

Exploring the concept of disease modification and related pathomechanisms in atopic dermatitis.

New Perspectives on <b>Disease</b> Modification in Atopic Dermatitis - Panel Discussion

expert video

New Perspectives on Disease Modification in Atopic Dermatitis - Panel Discussion

10 min

Dermatology

Panel discussion exploring what disease modification could involve in atopic dermatitis.

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Un<b>control</b>led and/or Severe CRSwNP

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

How do You Define Active <b>Disease</b> (CRSwNP) When Looking at the Nose With an Endoscope?

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

ADVENT On Air | Early Intervention and <b>Disease</b> Modification in Atopic Dermatitis

Podcast

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

20 min

Dermatology

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

Emerging Perspectives on the <b>Disease</b> Burden and Management of Children With Atopic Dermatitis

expert video

Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis

57 min

Dermatology

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region